Article

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature Review

2026-06-29

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphomas and is characterized by pronounced molecular heterogeneity that is not always fully captured by standard histopathological assessment. At present, analysis of circulating tumor DNA (ctDNA) is regarded as a promising liquid biopsy tool that enables non-invasive molecular tumor profiling, assessment of tumor burden,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c511471a-5027-5bc1-ad97-169a3a752002
DOI: 10.20944/preprints202606.2035.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewDOI 10.20944/preprints202606.2035.v1Read

Circulating Tumor DNA in Lymphoma: Principles and Future DirectionsSemantic proximity Read

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational researchSemantic proximity Read

Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity Read

The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas.Semantic proximity Read

Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas.Semantic proximity Read

Circulating Tumor DNA in Lymphoma.Semantic proximity Read

The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential.Semantic proximity Read

Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity Read

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read

Clinical use of circulating tumor DNA analysis in patients with lymphomaSemantic proximity Read

Analytical Validation of a Circulating Tumor DNA Assay using PhasED-Seq Technology for Detecting Residual Disease in B-Cell MalignanciesSemantic proximity Read

[Progression and application of circulating tumor DNA in lymphoma].Semantic proximity Read